Free tool
Drug Trial Radar: Pain and anesthesia
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
433
Completed, industry sponsors, Pain and anesthesia, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed433
433 trials
Showing 1 to 25, recently updated first.
- A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee OsteoarthritisPivotal-lookingCompleted
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07351968 · 202 participants · Start Mar 10, 2026 · Primary completion Jul 17, 2026
Drug: HRS-2129 Tablet; Celecoxib capsule and 2 more · For: Moderate Pain in Knee Osteoarthritis; Severe Pain in Knee Osteoarthritis
Sites: Nanjing, China
Hunan Kelun Pharmaceutical Co., Ltd.Industry
NCT07710560 · 27 participants · Start Jul 15, 2026 · Primary completion Aug 12, 2026
Drug: KL0011034 injection; Alfentanil Hydrochloride Injection · For: Chronic Pain
Sites: Changsha, China
South Rampart Pharma, Inc.Industry
NCT05484414 · 50 participants · Start Dec 30, 2021 · Primary completion Nov 6, 2023
Drug: SRP-3D (diethylamide); Placebo · For: Pain
Sites: Miami, Florida
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT07301333 · 80 participants · Start Dec 30, 2025 · Primary completion Jun 16, 2026
Drug: HRS-6257; placebo · For: Pain
Sites: Changsha, China
Bausch & Lomb IncorporatedIndustry
NCT07717918 · 28 participants · Start Jul 6, 2026 · Primary completion Aug 5, 2026
Drug: BL1332 eye drops; BL1332 Placebo eye drops · For: Healthy
Sites: Newport Beach, California
- Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female ParticipantsCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07378865 · 13 participants · Start Feb 13, 2026 · Primary completion Aug 17, 2026
Drug: Suzetrigine · For: Pain
Sites: Salt Lake City, Utah
4E TherapeuticsIndustry
NCT07586514 · 40 participants · Start Apr 18, 2025 · Primary completion Aug 18, 2025
Drug: LY4286533; placebo · For: Neuropathic Pain
Sites: Austin, Texas
MIRA PharmaceuticalsIndustry
NCT07791303 · 57 participants · Start Mar 20, 2025 · Primary completion Mar 5, 2026
Drug: Ketamir-2; Placebo · For: Healthy Adult Participants
Sites: Jerusalem, Israel
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07570069 · 18 participants · Start May 7, 2026 · Primary completion Jul 16, 2026
Drug: Suzetrigine; Efavirenz · For: Pain
Sites: Salt Lake City, Utah
JMackem Co., LtdIndustry
NCT06155487 · 76 participants · Start Dec 5, 2023 · Primary completion Apr 28, 2026
Drug: AJH-2947 tablets or placebo · For: Healthy Volunteers; Chronic Pain Syndrome
Sites: Seoul, South Korea
HALEONIndustry
NCT06855576 · 54 participants · Start Mar 5, 2025 · Primary completion Apr 17, 2025
Drug: Paracetamol ODT; Alvedon film-coated tablet and 1 more · For: Fever; Pain
Sites: Erfurt, Germany
- Safety, Tolerability and Pharmacokinetics of Meloxicam Nanocrystal Injection in Healthy SubjectsCompleted
Yangtze River Pharmaceutical Group Co., Ltd.Industry
NCT06902090 · 20 participants · Start Jul 5, 2023 · Primary completion Jul 25, 2023
Drug: Meloxicam Nanocrystal Injection(Yangtze River Pharmaceutical Group Co., Ltd.); Meloxicam Nanocrystal Injection (ANJESO®) · For: Pain
Sites: Chengdu, China
Heron TherapeuticsIndustry
NCT04398329 · 78 participants · Start May 8, 2020 · Primary completion Jul 15, 2021
Drug: HTX-034 low dose; HTX-034 high dose and 1 more · For: Bunions; Postoperative Pain
Sites: Phoenix, Arizona; Bellaire, Texas; San Antonio, Texas · 4 sites in all
- Clinical Study of HRS-2129 for Postoperative Analgesia in OrthopaedicsPivotal-lookingCompleted
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06780267 · 199 participants · Start Mar 11, 2025 · Primary completion Mar 19, 2026
Drug: HRS-2129; HRS-2129 placebo and 1 more · For: Postoperative Pain in Orthopaedics
Sites: Chengdu, China
- A Phase 1 Study of FZ008-145 in Healthy Subjects.Pivotal-lookingCompleted
Guangzhou Fermion Technology Co., LTDIndustry
NCT06685809 · 176 participants · Start Nov 25, 2024 · Primary completion Apr 14, 2026
Drug: FZ008-145 solution; FZ008-145 Tablet and 1 more · For: Healthy
Sites: Adelaide, Australia
LEO PharmaIndustry
NCT06444867 · 6 participants · Start Jan 7, 2025 · Primary completion Sep 18, 2025
Drug: LEO 158968 · For: Joint Pain; Gout Flares; Joint Inflammation
Sites: Lille, France; Venlo, Netherlands; London, United Kingdom
Persica Pharmaceuticals LtdIndustry
NCT04238676 · 43 participants · Start Jan 20, 2020 · Primary completion Dec 9, 2024
Drug: PP353 · For: Chronic Low-back Pain
Sites: Copenhagen, Denmark; Christchurch, New Zealand; Granada, Spain · 10 sites in all
Contineum TherapeuticsIndustry
NCT06810245 · 43 participants · Start Feb 4, 2025 · Primary completion Jan 20, 2026
Drug: PIPE-791; Placebo · For: Chronic Osteoarthritis Pain; Chronic Low Back Pain
Sites: Phoenix, Arizona; Marietta, Georgia; Hartsdale, New York · 5 sites in all
Imbrium TherapeuticsIndustry
NCT06285214 · 47 participants · Start May 26, 2022 · Primary completion Jan 28, 2025
Drug: V117957; Placebo · For: Interstitial Cystitis/Bladder Pain Syndrome
Sites: Homewood, Alabama; Tucson, Arizona; Little Rock, Arkansas · 24 sites in all
Haisco-USA Pharmaceuticals, Inc.Industry
NCT07404306 · 43 participants · Start Aug 16, 2022 · Primary completion Oct 3, 2023
Drug: HSK3486; propofol and 1 more · For: General Anesthesia
Sites: Salt Lake City, Utah
Cullgen Australia Pty LtdIndustry
NCT06636500 · 72 participants · Start Jan 22, 2025 · Primary completion Dec 5, 2025
Drug: CG001419; Placebo · For: Healthy Volunteer Study; Pain Management
Sites: Adelaide, Australia
Joincare Pharmaceutical Group Industry Co., LtdIndustry
NCT07412938 · 44 participants · Start Feb 12, 2025 · Primary completion Jul 2, 2025
Drug: JKN2306; Placebo · For: Acute Pain
Sites: Beijing, China
Latigo BiotherapeuticsIndustry
NCT07341152 · 14 participants · Start Oct 6, 2025 · Primary completion Nov 17, 2025
Drug: LTG-001 SDD; LTG-001 Formulation A Prototype 1 and 2 more · For: Pain Management
Sites: Miami, Florida
Haisco-USA Pharmaceuticals, Inc.Industry
NCT06795204 · 48 participants · Start Apr 9, 2024 · Primary completion May 19, 2024
Drug: HSK3486; Moxifloxacin Hydrochloride and 1 more · For: Anesthesia; Adverse Effect; Cardiac Arrhythmia
Sites: Beijing, China
Cytonics CorporationIndustry
NCT06263270 · 19 participants · Start Jun 1, 2024 · Primary completion Mar 15, 2025
Drug: CYT-108, a recombinant protease inhibitor · For: Osteoarthritis, Knee; Osteoarthritis
Sites: Sunshine Coast, Australia; Kotara, Australia; Camberwell, Australia
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.